← 返回

核输出蛋白 XPO1 为 NK 细胞提供肽配体

英文原题:The nuclear export protein XPO1 provides a peptide ligand for natural killer cells.

查看英文原题

The nuclear export protein XPO1 provides a peptide ligand for natural killer cells.

PubMed 2024/08/23(内容时间) Sci Adv Q1 · IF 13.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

XPO1(Exportin-1/CRM1)是一种核输出蛋白,在癌症中常过表达,并作为肿瘤发生的驱动因素发挥作用。目前,靶向XPO1的小分子正作为抗癌药物在临床中使用。我们将XPO1确定为自然杀伤(NK)细胞的靶点。利用免疫肽组学,我们鉴定出一种来源于XPO1的肽,其可在人类白细胞抗原-C的背景下被活化性NK细胞受体KIR2DS2识别。该肽可被内源性加工并呈递,以通过该受体特异性激活NK细胞。尽管癌症中XPO1高表达通常与不良预后相关,但我们表明,如果同时存在NK细胞浸润的证据,某些特定癌症(如肝细胞癌)的结局可显著改善。因此,我们将XPO1确定为一种被NK细胞识别的真正的肿瘤抗原,其为实体瘤NK细胞治疗的个体化方法提供了机会。

展开英文摘要原文

XPO1 (Exportin-1/CRM1) is a nuclear export protein that is frequently overexpressed in cancer and functions as a driver of oncogenesis. Currently small molecules that target XPO1 are being used in the clinic as anticancer agents.

We identify XPO1 as a target for natural killer (NK) cells. Using immunopeptidomics, we have identified a peptide derived from XPO1 that can be recognized by the activating NK cell receptor KIR2DS2 in the context of human leukocyte antigen-C. The peptide can be endogenously processed and presented to activate NK cells specifically through this receptor.

Although high XPO1 expression in cancer is commonly associated with a poor prognosis, we show that the outcome of specific cancers, such as hepatocellular carcinoma, can be substantially improved if there is concomitant evidence of NK cell infiltration.

We thus identify XPO1 as a bona fide tumor antigen recognized by NK cells that offers an opportunity for a personalized approach to NK cell therapy for solid tumors.

论文信息

作者
Blunt MD、Fisher H、Schittenhelm RB、Mbiribindi B、Fulton R、Khan S、Espana-Serrano L、Graham LV
单位
School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.United Kingdom
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Science advances2024 Aug 23
原文标识
PubMed 39178254 · DOI 10.1126/sciadv.ado6566